Nektar Therapeutics buy Bankster
Start price
13.03.23
/
50%
€1.11
Target price
13.03.24
-
Performance (%)
-43.01%
End price
03.04.23
€0.63
Summary
This prediction ended on 03.04.23 with a price of €0.63. Massive losses of -43.01% were the result for the BUY prediction by Bankster. Bankster has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | -11.776% | -11.776% | 133.964% |
| iShares Core DAX® | -0.448% | 2.344% | 15.948% |
| iShares Nasdaq 100 | 0.834% | 5.019% | 30.983% |
| iShares Nikkei 225® | -0.479% | 0.550% | 9.206% |
| iShares S&P 500 | -0.352% | 2.631% | 26.224% |
Comments by Bankster for this prediction
In the thread Nektar Therapeutics diskutieren
Buy Nektar Therapeutics